Helus Pharma Plans to Present Phase 3 APPROACH Results for HLP003 as an Adjunctive Depression Treatment
Summary
Helus Pharma plans to present topline results from its Phase 3 APPROACH study of HLP003 as an adjunctive treatment for major depressive disorder in a webcast on November 16, 2026. The company says HLP003 is a proprietary synthetic serotonergic agonist and has received FDA Breakthrough Therapy Designation. An archived webcast is planned after the presentation. The announcement does not disclose the study results or establish the treatment's efficacy or safety. Helus cautions that regulatory approval is not assured and that further scientific research and clinical trials are needed.